DE60216097D1 - Phenylacetamido-thiazole verbindungen, verfahren zu ihren herstellung und ihre anwendung als antitumor mittel - Google Patents

Phenylacetamido-thiazole verbindungen, verfahren zu ihren herstellung und ihre anwendung als antitumor mittel

Info

Publication number
DE60216097D1
DE60216097D1 DE60216097T DE60216097T DE60216097D1 DE 60216097 D1 DE60216097 D1 DE 60216097D1 DE 60216097 T DE60216097 T DE 60216097T DE 60216097 T DE60216097 T DE 60216097T DE 60216097 D1 DE60216097 D1 DE 60216097D1
Authority
DE
Germany
Prior art keywords
phenylacetamido
production
antitumor agents
thiazole compounds
thiazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60216097T
Other languages
English (en)
Other versions
DE60216097T2 (de
Inventor
Paolo Pevarello
Raffaella Amici
Manuela Villa
Barbara Salom
Anna Vulpetti
Mario Varasi
Gabriella Brasca
Gabriella Traquandi
Marcella Nesi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Pfizer Italia SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Italia SRL filed Critical Pfizer Italia SRL
Publication of DE60216097D1 publication Critical patent/DE60216097D1/de
Application granted granted Critical
Publication of DE60216097T2 publication Critical patent/DE60216097T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60216097T 2001-07-19 2002-07-02 Phenylacetamido-thiazole verbindungen, verfahren zu ihren herstellung und ihre anwendung als antitumor mittel Expired - Lifetime DE60216097T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US90794701A 2001-07-19 2001-07-19
US907947 2001-07-19
US35764202P 2002-02-20 2002-02-20
US357642P 2002-02-20
PCT/EP2002/007289 WO2003008365A2 (en) 2001-07-19 2002-07-02 Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents

Publications (2)

Publication Number Publication Date
DE60216097D1 true DE60216097D1 (de) 2006-12-28
DE60216097T2 DE60216097T2 (de) 2007-06-28

Family

ID=26999733

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60216097T Expired - Lifetime DE60216097T2 (de) 2001-07-19 2002-07-02 Phenylacetamido-thiazole verbindungen, verfahren zu ihren herstellung und ihre anwendung als antitumor mittel

Country Status (25)

Country Link
US (1) US20040235919A1 (de)
EP (1) EP1406899B1 (de)
JP (1) JP2004534857A (de)
KR (1) KR100908794B1 (de)
CN (1) CN1286835C (de)
AR (1) AR036176A1 (de)
AT (1) ATE345341T1 (de)
AU (1) AU2002325860B2 (de)
BR (1) BR0211265A (de)
CA (1) CA2453294A1 (de)
CY (1) CY1105948T1 (de)
CZ (1) CZ2004107A3 (de)
DE (1) DE60216097T2 (de)
DK (1) DK1406899T3 (de)
EA (1) EA007392B1 (de)
ES (1) ES2274076T3 (de)
GE (1) GEP20105095B (de)
HK (1) HK1068336A1 (de)
IL (2) IL159570A0 (de)
MX (1) MXPA04000407A (de)
NO (1) NO20040210L (de)
NZ (1) NZ530524A (de)
PL (1) PL367938A1 (de)
PT (1) PT1406899E (de)
WO (1) WO2003008365A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2576599A1 (en) * 2004-08-17 2006-02-23 F. Hoffmann-La Roche Ag Substituted hydantoins
TW200621766A (en) * 2004-09-17 2006-07-01 Hoffmann La Roche Substituted hydantoins
EP1812439B2 (de) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinaseinhibitoren
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
US8168794B2 (en) 2008-03-03 2012-05-01 Novartis Ag Pim kinase inhibitors and methods of their use
EP2861585B1 (de) 2012-05-21 2019-01-09 Novartis AG Neuartige ringsubstituierte n-pyridinylamide als kinasehemmer
WO2014085607A1 (en) 2012-11-29 2014-06-05 Karyopharm Therapeutics Inc. Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof
BR112015032921B1 (pt) 2013-07-03 2022-06-14 Karyopharm Therapeutics, Inc Compostos de benzofuranila e benzoxazolila substituídos e utilizações dos mesmos
WO2015042414A1 (en) * 2013-09-20 2015-03-26 Karyopharm Therapeutics Inc. Multicyclic compounds and methods of using same
AU2016308829A1 (en) 2015-08-18 2018-03-08 Karyopharm Therapeutics Inc. (s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl)-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer
US10858347B2 (en) 2015-12-31 2020-12-08 Karyopharm Therapeutics Inc. Multicyclic compounds and uses thereof
CA3106855A1 (en) * 2018-09-17 2020-03-26 Yungjin Pharm. Co., Ltd. Thiazole derivatives and pharmaceutically acceptable salts thereof
WO2021182914A1 (ko) * 2020-03-13 2021-09-16 영진약품 주식회사 신규한 cdk7 억제 화합물 및 이의 약제학적으로 허용가능한 염
CN112979634A (zh) * 2021-02-06 2021-06-18 绍兴文理学院 一种含酰胺结构的噻唑类化合物及其制备方法和应用
CN112979636A (zh) * 2021-02-06 2021-06-18 绍兴文理学院 一种含苯硫醚结构的噻唑类化合物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6214852B1 (en) 1998-10-21 2001-04-10 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
US6114365A (en) * 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents

Also Published As

Publication number Publication date
AU2002325860B2 (en) 2008-03-13
KR100908794B1 (ko) 2009-07-22
MXPA04000407A (es) 2004-03-18
ATE345341T1 (de) 2006-12-15
WO2003008365A2 (en) 2003-01-30
PL367938A1 (en) 2005-03-07
EP1406899B1 (de) 2006-11-15
AR036176A1 (es) 2004-08-18
EA007392B1 (ru) 2006-10-27
EP1406899A2 (de) 2004-04-14
IL159570A0 (en) 2004-06-01
WO2003008365A3 (en) 2004-02-12
KR20040030821A (ko) 2004-04-09
CN1286835C (zh) 2006-11-29
HK1068336A1 (en) 2005-04-29
ES2274076T3 (es) 2007-05-16
NZ530524A (en) 2006-12-22
CN1531535A (zh) 2004-09-22
CZ2004107A3 (cs) 2004-04-14
IL204947A0 (en) 2010-11-30
US20040235919A1 (en) 2004-11-25
BR0211265A (pt) 2004-07-20
EA200400208A1 (ru) 2004-06-24
DK1406899T3 (da) 2007-04-02
PT1406899E (pt) 2007-01-31
JP2004534857A (ja) 2004-11-18
GEP20105095B (en) 2010-10-25
CY1105948T1 (el) 2011-04-06
CA2453294A1 (en) 2003-01-30
NO20040210L (no) 2004-03-03
DE60216097T2 (de) 2007-06-28

Similar Documents

Publication Publication Date Title
DE50214717D1 (de) Und verfahren zu seiner herstellung
DE502004011957D1 (de) Neue cyanopyrrolidide, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE50209103D1 (de) Filterverbund und verfahren zu seiner herstellung
DE60215922D1 (de) Filterelement, verfahren zu seiner herstellung und das element verwendender filter
DE60208373D1 (de) Polyaryleneether-polyolefinzusammensetzung, verfahren zu deren herstellung und formassen daraus
DE60216097D1 (de) Phenylacetamido-thiazole verbindungen, verfahren zu ihren herstellung und ihre anwendung als antitumor mittel
DE602004021927D1 (de) Halbleiterbauelement und verfahren zu seiner herstellung
DE60141211D1 (de) Polysilizium-halbleiterbauteil und verfahren zu dessen herstellung
DE60206141D1 (de) Honigwabenfilter und verfahren zu dessen herstellung
DE50213224D1 (de) Induktives bauelement und verfahren zu seiner herstellung
DE60325690D1 (de) Halbleiterbauelement und verfahren zu seiner herstellung
DE50207522D1 (de) Neue dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
DE60209104D1 (de) Selbstdichtender reifen und verfahren zu dessen herstellung
ATE471931T1 (de) Verbindungen, zusammensetzungen und verfahren
ATA10852001A (de) Bauelement und verfahren zu seiner herstellung
DE60337036D1 (de) Halbleiterbauelement und verfahren zu seiner herstellung
ATE327981T1 (de) Arylisoxazolin-derivative, verfahren zu ihrer herstellung und ihre verwendung als schädlingsbekämpfungsmittel
DE50213327D1 (de) Anbaueinrichtung, Fahrzeug und Verfahren
DE50209101D1 (de) Hitzebeständige filterlage, filterkörper und verfahren zu seiner herstellung
DE50310782D1 (de) Piezoaktor und verfahren zu dessen herstellung
DE60124428D1 (de) Lüftungsvorrichtung und verfahren zu dessen herstellung
DE602004008991D1 (de) Umlenkbeschlag und verfahren zu dessen herstellung
DE60224880D1 (de) Mikrobolometer und verfahren zu dessen herstellung
DE60239493D1 (de) Halbleiterbauelement und verfahren zu seiner herstellung
DE60319717D1 (de) Spandexfaser mit ethylendiamin/1,2-diaminopropan als kettenverlängerer und verfahren zu dessen herstellung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition